Skip to main content

Table 2 Reason for and characteristics of switching

From: Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

 

Total N(748)

4 mg N(226)

8 mg N(509)

<65 yr. N(418)

≥65 yr. N(330)

Driven treatment change, %

     

 Patient request

24.8

29.8

21.7

24.7

24.9

 Investigator decision

75.2

70.2

78.3§

75.3

75.1

Principal reason for switching, %

     

 Lack of effectiveness

66.8

58.0

70.9§

67.0

66.7

 Side-effects

18.4

23.5

16.1

17.0

20.3

 Bad compliance

6.1

8

5.3

7.2

4.8

 Others

8.5

10.5

7.7

8.9

8.2

Treatment length‡, mean (SD), d.

66.2(36.2)

60.1(34.8)

68.8(36.7)§

63.8(36.1)

69.2(36.2)§

Treatment compliance £, %

31.0

24.9

33.5§

31.6

30.3

  1. ‡at the time of study visit; £:% of compliers (4 Morinsky-Green questions answered correctly); *:p between groups < 0.001; §:p between groups < 0.05.